Skip to content
Search our Site
Search our site
Search our site
My PD Journey
About the EPDA
Political affairs and policy
Medical and pharmaceutical
Political and policy
World PD Day News
Resources and publications
Addex dipraglurant shows significant anti-dyskinetic effects following analysis of data from PD-LID phase II proof of concept
Addex Therapeutics, a leading company pioneering allosteric modulation-based drug discovery and development, announced today that dipraglurant shows a statistically significant anti-dyskinetic effect, over the total treatment duration of 28 days, following additional analysis of the previously reported data from the Parkinson's disease levodopa-induced dyskinesia Phase II proof of concept (POC) clinical trial.
11 January 2016
Cynapsus & MJ Fox Foundation collaborate on pilot use of wearable device & data science approaches in Phase 3 PD clinical study
Cynapsus Therapeutics Inc. and The Michael J. Fox Foundation for Parkinson's Research today announced that they are working together to incorporate wearable device technology and big data approaches into Cynapsus' pivotal Phase 3 clinical study of APL-130277, a sublingual formulation of apomorphine to treat (OFF) episodes in Parkinson's disease patients.
07 January 2016
Use of anticholinergic drugs does not increase risk for dementia in Parkinson's disease patients
Concern that anticholinergics could potentially worsen cognition in Parkinson's disease unfounded, according to new research reported in the Journal of Parkinson's Disease.
05 January 2016
Adamas announces positive phase 3 results of ADS-5102 for treatment of levodopa-induced dyskinesia in patients with Parkinson's
Adamas Pharmaceuticals, Inc. today announced that its Phase 3 EASE LID clinical trial evaluating the company's investigational compound ADS-5102 (amantadine HCl) extended-release capsules for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson's disease met its primary endpoint.
23 December 2015
CANTABio & Gardedam Therapeutics complete merger to tackle development of novel therapeutics for Alzheimer's & Parkinson's
Cantabio Pharmaceuticals, Inc. ("Cantabio") is pleased to announce the completion of its reverse merger (the "Merger") with Gardedam Therapeutics, Inc. ("Gardedam"). The effective date of the Merger is December 18th, 2015.
21 December 2015
Subscribe to this page >
Back to Top
Add page to PDF basket
Copyright © 2016 EPDA. All Rights Reserved.
Privacy and cookies